Chronic myeloid leukemia (CML) tumorigenicity is driven by the oncogenic BCR-ABL
tyrosine kinase. Specific tyrosine kinase inhibitors (TKI) have been designed and are now …

It is an important challenge to better understand the mechanisms of tyrosine kinase
inhibitors-induced apoptosis in CML cells. Thus, we have investigated how this apoptosis …

Chronic myeloid leukemia (CML) is a myeloproliferative disease in which BCR/ABL
enhances survival of leukemic cells through modulation of proapoptotic and antiapoptotic …

BCR-ABL1-specific tyrosine kinase inhibitors prolong the life of patients with chronic myeloid
leukemia (CML) but cannot completely eradicate CML progenitors. The BH3 mimetic, ABT …

Bcr-Abl tyrosine kinase has been validated as a molecular target for the treatment of chronic
myelogenous leukemia (CML). More recently, it has been reported that CML patients could …

Imatinib is an effective first-line therapy for chronic myelogenous leukemia (CML) that acts
by targeting the tyrosine kinase activity of BCR–ABL. To overcome resistance, second …

Chronic myeloid leukemia (CML) is characterized by a constitutive activation of Bcr-Abl
tyrosine kinase. Bcr-Abl/T315I is the predominant mutation that causes resistance to …

Imatinib mesylate (Gleevec) is effective therapy against Philadelphia chromosome–positive
leukemia, but resistance develops in all phases of the disease. Bcr/Abl point mutations and …

Imatinib is a selective breakpoint cluster region–Abelson (BCR-ABL) tyrosine kinase
inhibitor (TKI) that has significantly improved the prognosis of patients with chronic myeloid …

Acute myeloid leukemia (AML) is a serious disease. The 5-year survival rates remain
frustratingly low (65% for children and 26% for adults). Resistance to frontline chemotherapy …